• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Syngene

    Cytovance Biologics

    Flow Sciences

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Flow Sciences

    Reed-Lane

    Emergent BioSolutions

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    PAI Readiness – A Journey, not an Event

    A look at what you need to do to get ready for a pre-approval inspection

    PAI Readiness – A Journey, not an Event
    Related CONTENT
    • Vetio Animal Health
    • Semi-Solid Dosage Forms
    • Stellar Announces Positive Third-Party Trial Results
    • Cytovance Biologics Completes FDA Inspection
    • Janssen's Supply Chain VP Talks Trends
    Dr. Walter Matzmorr, Tunnell Consulting06.12.18
    Being ready for a Pre-Approval Inspection (PAI) is a key milestone for the successful approval of a new product and can significantly impact the approval timeline and time to market. For companies who have experience in product development and commercialization, getting ready for a PAI is built into their development process, but small companies and biotech startups who want to get their first product approved often struggle to determine if they are ready for a PAI. Avoiding this uncertainty requires thorough preparation. Utilizing external, independent reviews and assessments minimizes the risk of surprises and maximizes the best use of limited internal resources.

    PAI readiness is not a one-time event that can be achieved through assessments and training alone; it is a cross-functional process with multiples phases that include elements of technical and regulatory compliance, organizational aspects, training, and product, process, and method validation.

    The FDA conducts a PAI to ensure that a manufacturing establishment named in a drug application is capable of manufacturing and/or testing a drug and that the submitted data are accurate and complete.

    What does this mean for the main objectives for a PAI? Being capable of manufacturing a drug includes the methods or processes, the facilities and the controls used to manufacture a drug. It requires compliance with CGMP regulations, robust product, process and method validation, adequately established quality systems, an appropriate quality risk management system as well as compliance with other applicable, process or product specific regulations. However, being capable of manufacturing a product is by far not enough to pass a PAI. During the PAI, the FDA will verify that the actual process including test methods are in conformance with the original application and that the established approach and practices for data management ensure the integrity of the data that have been generated and used in development, manufacturing, monitoring and product testing. All this will be assessed during a PAI so that the main objectives can be summarized as follows:
    • Confirm the Readiness for Commercial Manufacturing
    • Verify the Conformance to Application
    • Verify Data Integrity / Conduct a Data Integrity Audit
    Figure 1 shows how these objectives are interconnected with each other.


    Figure 1. Interconnected Objectives of a PAI

    Risk-based approach
    The three main objectives of a PAI cover a wide field that spans for a new product from the development phase to the current manufacturing footprint, which very often includes third party manufacturing sites and contract testing labs. However, there are situations, where PAIs can be more limited like in the case of a change in the manufacturing site or a major process change. This is why the FDA typically applies risk based priority inspection criteria, making the inspection breadth decision based on the following risks:
    • Facility Risk
    • Product Risk
    • Process Risk
    A startup company with a new product and new process technology in a new facility scores high in all risk areas listed above, whereas in the case of a transfer of an approved product to a brand-new facility, facility risks would be the primary focus.

    The journey
    Typically we see two different scenarios in which sites or organizations need to prepare for a PAI.

    Scenario 1. For established organizations experienced in CGMP operations and experienced in PAIs, a Mock PAI that simulates a real inspection situation is typically the way to go. The Mock PAI should include inspection training and coaching. Any findings or observations during the Mock PAI should be addressed accordingly.

    Scenario 2. For organizations with no or limited CGMP experience that are preparing for their first PAI, a one-time status check in the form of a Mock Inspection is predictably insufficient. In these cases, the PAI preparation needs to include a significant transformation moving out of a research and development environment and mindset into the CGMP, commercial production world. This transformation challenges many parts of the organization, but it is a fundamental change that should be carefully reflected and embedded into the overall preparation plan.

    Because a PAI is a critical milestone for any company, an approach that includes the sustainable and long-term development of PAI Readiness minimizes the risk of any PAI, but this requires advanced, appropriate planning to meet the key milestones on the journey to PAI Readiness.

    The journey towards PAI preparedness incorporates the following milestones:
    1. Technical Readiness
    2. GMP Readiness
    3. PAI Readiness
    In cases described in Scenario 1, technical readiness and GMP readiness are theoretically already successfully established and PAI Readiness could be verified through assessments,  audits and a Mock Inspection, but for “first timers” as described in Scenario 2 this journey is an endeavor that takes significant time and resources. As with every journey into new territory a roadmap and guidance from experienced travelers helps ensure that all critical milestones are met and that the final destination is reached on time. Figure 2 shows a high level timeline and key milestones on the journey towards PAI readiness and a successful PAI.


    Figure 2. Steps towards PAI Readiness

    Depending on the situation, it can take up to two years or more to achieve PAI Readiness. This estimation includes the time to get a facility to Technical Readiness and to train personnel and establish proper procedures and supporting quality systems to ensure compliance with CGMPs.

    For start-up companies, the main challenge is to ensure that during this timeframe all elements that are critical to achieve Technical Readiness and GMP Readiness have been sufficiently addressed. Otherwise, the Mock inspection could uncover critical issues that would potentially impact the chances of a timely and successful PAI.

    The first step is to ensure that a facility achieves the Technical Readiness milestone for technical transfer and engineering runs. This requires that the equipment is installed and operates as intended. This should be verified through successful commissioning and qualification, planned and successfully executed based on a pre-defined and pre-approved Commissioning and Qualification plan. At this point, it is also required that the process description is in final draft form. Additionally, the basic outline of the process validation plan and the process control strategy should have been developed and that appropriate test methods, change control procedures and good documentation practices are in place.

    The second milestone, GMP Readiness, is achieved when the process description and the master batch records are finalized, the process control strategy has been defined and appropriate, sustainable quality systems are implemented. The verification of GMP Readiness typically requires area-specific audits, comprehensive training programs and coaching, where appropriate. From a practical perspective it should be considered that at this point critical aspects of future manufacturing performance and efficiency will be defined. All facility, manufacturing and testing related processes need to be established.  It should be verified to ensure that they are compliant with applicable CGMP regulations, but it should be also verified that they are “fit for purpose.” This applies to manufacturing and supporting process-related SOPs, Master Batch Records, environmental monitoring programs, and governing quality systems. They need to be designed in a way that all processes and procedures are clearly defined and efficient and ensure compliance. Most of us have seen batch records with 150 pages and more, but also examples with about 50 pages for comparable processes. It is also very likely that many, if not all, of us have seen change control and deviations investigation forms that are signed off by more individuals than the Declaration of Independence. It is much easier and more efficient to implement a streamlined process with clear roles and responsibilities from the beginning rather than trying to optimize it at a later point in time.  Bringing experienced coaches on board that know what to do, how to do it and when to do it, adds value, ensures that CGMP compliance, efficiencies, and “fit for purpose” are aligned while preparing for GMP readiness.

    Once the two first milestones have been achieved the final phase to PAI Readiness typically includes inspection training and coaching to ensure that the logistical and organizational challenges for the PAI are understood and that the site team is properly prepared to manage them.

    Hands-on training and coaching for inspection situations in different areas should be included and cover all levels of a site organization from site management to shop floor operators. Experienced coaches can provide guidance on how to respond to questions and how to handle different types of inspectional situations as well as managing the overall inspection process. The final litmus test is a Mock Inspection, which simulates a real inspection situation. Once the Mock Inspection has been executed and any potential findings of the inspection have been suitably addressed, the goal of PAI Readiness has been achieved.

    Table 1 summarizes the main elements for each Readiness Milestone that need to be in place.


    Table 1. Milestones to PAI Readiness

    Conclusion
    PAI Readiness has a lot of challenging aspects especially for young organizations and/or “first timers.” Like many other things that are done for the first time, it comes with a level of uncertainty. Successful preparation of PAI Readiness requires well-informed planning and diligent preparation. A PAI is much more than a routine GMP inspection that the FDA conducts on a regular basis. A PAI is the final verification that a company has the right procedures and processes in place to manufacture a product under CGMPs and that the actual process conditions and parameters are in conformance with the product filing.

    The level of complexity and experience of the organization dictates the time required for planning in advance of an expected PAI to avoid last minute surprises. The use of experienced coaches who can act as guides and advisors is a way to minimize PAI inspection risks and also to ensure that process controls and quality systems are “fit for purpose,” compliant and efficient from the start. 


    Dr. Walter Matzmorr has more than 30 years’ experience in process development, manufacturing and engineering within the biopharmaceutical industry. His expertise includes aseptic processing, filling and lyophilization, good manufacturing practices (GMP), and process optimization and facility start up. He also has in-depth experience in dealing with regulatory agencies in the U.S. and Europe. walter.matzmorr@tunnellconsulting.com
    Related Searches
    • Development
    • GMP
    • cGMP
    • pre-approval inspection
    Suggested For You
    Vetio Animal Health Vetio Animal Health
    Semi-Solid Dosage Forms Semi-Solid Dosage Forms
    Stellar Announces Positive Third-Party Trial Results Stellar Announces Positive Third-Party Trial Results
    Cytovance Biologics Completes FDA Inspection Cytovance Biologics Completes FDA Inspection
    Janssen Janssen's Supply Chain VP Talks Trends
    Drug Safety Update Drug Safety Update
    Finding Value in Quality Contract Manufacturing Finding Value in Quality Contract Manufacturing
    From OMUFA To Opioids From OMUFA To Opioids
    Sterile Fill & Finish Sterile Fill & Finish
    HHS 2019 Budget Proposal: Key Priorities Impacting Pharma HHS 2019 Budget Proposal: Key Priorities Impacting Pharma
    Cellenkos Completes FDA Registration of GMP Mfg. Facility Cellenkos Completes FDA Registration of GMP Mfg. Facility
    Pii Receives 7 Market Approvals from FDA in 2017 Pii Receives 7 Market Approvals from FDA in 2017
    An Interactive Global Map of Pharma Manufacturing Sites An Interactive Global Map of Pharma Manufacturing Sites
    Sobi Receives IND Acceptance from FDA Sobi Receives IND Acceptance from FDA
    Cytovance Hires Quality VP Cytovance Hires Quality VP

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login